Neurobiological links between depression and AD: the role of TGF-β1 signaling as a new pharmacological target
In the last several years a large number of studies have demonstrated the neurobiological
and clinical continuum between depression and Alzheimer's disease (AD). Depression is a …
and clinical continuum between depression and Alzheimer's disease (AD). Depression is a …
Depression and Alzheimer's disease: neurobiological links and common pharmacological targets
Depression is one of the most prevalent and life-threatening forms of mental illnesses,
whereas Alzheimer's disease is a neurodegenerative disorder that affects more than 37 …
whereas Alzheimer's disease is a neurodegenerative disorder that affects more than 37 …
Pathways connecting late-life depression and dementia
C Linnemann, UE Lang - Frontiers in pharmacology, 2020 - frontiersin.org
Late-life depression is associated with significant cognitive impairment. Meta-analyses
showed that depression is associated with an increased risk for Alzheimer's disease (AD) …
showed that depression is associated with an increased risk for Alzheimer's disease (AD) …
Depression in Alzheimer's disease: epidemiology, mechanisms, and management
S Chi, JT Yu, MS Tan, L Tan - Journal of Alzheimer's disease, 2014 - content.iospress.com
Depression occurs with a high prevalence of up to 50% in patients with Alzheimer's disease
(AD) and increases the caregivers' burden. Depression symptoms can precede clinical …
(AD) and increases the caregivers' burden. Depression symptoms can precede clinical …
Neuropathological relationship between major depression and dementia: a hypothetical model and review
Major depression (MDD) is a chronic psychiatric condition in which patients often show
increasing cognitive impairment with recurring episodes. Neurodegeneration may play an …
increasing cognitive impairment with recurring episodes. Neurodegeneration may play an …
Transforming growth factor beta type I role in neurodegeneration: implications for Alzheimer s disease
LD Estrada, L Oliveira-Cruz… - Current Protein and …, 2018 - ingentaconnect.com
Alzheimer's disease is a neurodegenerative condition affecting millions of people
worldwide. Alzheimer's symptoms include memory loss and cognitive decline …
worldwide. Alzheimer's symptoms include memory loss and cognitive decline …
TGF-β/Smad signalling in neurogenesis: implications for neuropsychiatric diseases
TGF-β/Smad signalling has been the subject of extensive research due to its role in the cell
cycle and carcinogenesis. Modifications to the TGF-β/Smad signalling pathway have been …
cycle and carcinogenesis. Modifications to the TGF-β/Smad signalling pathway have been …
The CC genotype of transforming growth factor-β1 increases the risk of late-onset Alzheimer's disease and is associated with AD-related depression
F Caraci, P Bosco, M Signorelli, RS Spada… - European …, 2012 - Elsevier
Transforming growth factor-β1 (TGF-β1) is a neurotrophic factor that exerts neuroprotective
effects against β-amyloid-induced neurodegeneration. Recently, a specific impairment of the …
effects against β-amyloid-induced neurodegeneration. Recently, a specific impairment of the …
TGF‐β1 Pathway as a New Target for Neuroprotection in Alzheimer's Disease
Alzheimer's disease (AD) is a neurodegenerative disorder that affects more than 37 million
people worldwide. Current drugs for AD are only symptomatic, but do not interfere with the …
people worldwide. Current drugs for AD are only symptomatic, but do not interfere with the …
Dysfunction of TGF-β1 signaling in Alzheimer's disease: perspectives for neuroprotection
F Caraci, S Spampinato, MA Sortino, P Bosco… - Cell and tissue …, 2012 - Springer
Alzheimer's disease (AD) is a neurodegenerative disorder that affects about 35 million
people worldwide. Current drugs for AD only treat the symptoms and do not interfere with the …
people worldwide. Current drugs for AD only treat the symptoms and do not interfere with the …